Given Imaging gets Bravo from Medtronic
This article was originally published in The Gray Sheet
Executive SummaryGiven Imaging acquires Medtronic's Bravo wireless gastroesophageal reflux disease monitor business for $20 million Dec. 8. The catheter-free GERD test, which uses a disposable capsule temporarily placed in the esophagus to measure pH levels and transmit data to an external receiver, will add about $12 million to Given's sales in 2009, the firm predicts. Bravo "is a synergistic and strategic fit" with Given's PillCam video capsule-based diagnostic system for gastrointestinal disorders, according to the company
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.